Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Greenbaum

Showing results (161-170 of 225) with videos related to

Pageof 23
Sort By:
Diabetologia|August 4, 2017
Understanding and preventing type 1 diabetes through the unique working model of TrialNetManuela Battaglia, Mark S Anderson, Jane H Buckner, et al.
Diabetes Care|December 29, 2006
Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1Jay M Sosenko, Jerry P Palmer, Carla J Greenbaum, et al.
Diabetes Care|March 1, 2006
Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1Jay M Sosenko, Jerry P Palmer, Carla J Greenbaum, et al.
Science Translational Medicine|September 16, 2016
Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expressionChristian Hundhausen, Alena Roth, Elizabeth Whalen, et al.
Diabetes Care|December 19, 2014
A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural historyJay M Sosenko, Jay S Skyler, Linda A DiMeglio, et al.
Diabetes|February 13, 2024
Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 DiabetesEsther Latres, Carla J Greenbaum, Maria L Oyaski, et al.
Diabetes Care|March 27, 2012
Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodiesLiping Yu, David C Boulware, Craig A Beam, et al.
Scandinavian Journal of Immunology|January 10, 2006
Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitopeD G Alleva, R A Maki, A L Putnam, et al.
Diabetes|July 10, 2013
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of respondersKevan C Herold, Stephen E Gitelman, Mario R Ehlers, et al.
Diabetologia|December 21, 2018
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosisAna Luisa Perdigoto, Paula Preston-Hurlburt, Pamela Clark, et al.
Pageof 23

Showing results (161-170 of 225) with videos related to

Sort By:
Pageof 23
Diabetologia|August 4, 2017
Understanding and preventing type 1 diabetes through the unique working model of TrialNetManuela Battaglia, Mark S Anderson, Jane H Buckner, et al.
Diabetes Care|December 29, 2006
Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1Jay M Sosenko, Jerry P Palmer, Carla J Greenbaum, et al.
Diabetes Care|March 1, 2006
Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1Jay M Sosenko, Jerry P Palmer, Carla J Greenbaum, et al.
Science Translational Medicine|September 16, 2016
Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expressionChristian Hundhausen, Alena Roth, Elizabeth Whalen, et al.
Diabetes Care|December 19, 2014
A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural historyJay M Sosenko, Jay S Skyler, Linda A DiMeglio, et al.
Diabetes|February 13, 2024
Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 DiabetesEsther Latres, Carla J Greenbaum, Maria L Oyaski, et al.
Diabetes Care|March 27, 2012
Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodiesLiping Yu, David C Boulware, Craig A Beam, et al.
Scandinavian Journal of Immunology|January 10, 2006
Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitopeD G Alleva, R A Maki, A L Putnam, et al.
Diabetes|July 10, 2013
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of respondersKevan C Herold, Stephen E Gitelman, Mario R Ehlers, et al.
Diabetologia|December 21, 2018
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosisAna Luisa Perdigoto, Paula Preston-Hurlburt, Pamela Clark, et al.
Pageof 23